Skip to main content
Top
Published in: Endocrine 3/2020

01-12-2020 | Hemithyroidectomy | Original Article

The extent of surgery for low-risk 1–4 cm papillary thyroid carcinoma: a catch-22 situation. A retrospective analysis of 497 patients based on the 2015 ATA Guidelines recommendation 35

Authors: Emma Anda Apiñániz, Carles Zafon, Irati Ruiz Rey, Carolina Perdomo, Javier Pineda, Juan Alcalde, Marta García Goñi, Juan C. Galofré

Published in: Endocrine | Issue 3/2020

Login to get access

Abstract

Purpose

The adequate extent of surgery for 1–4 cm low-risk papillary thyroid carcinoma (PTC) is unclear. Our objective was to analyze the applicability of the 2015 ATA Guidelines recommendation 35B (R35) for the management low-risk PTC.

Methods

This multicentre study included patients with low-risk PTC who had undergone total thyroidectomy (TT). Retrospectively we selected those who met the R35 criteria for the performance of a thyroid lobectomy (TL). The aim was to identify the proportion of low-risk PTC patients treated using TT who would have required reintervention had they had a TL in accordance with R35.

Results

We identified 497 patients (400 female; 80.5%). Median tumor size (mm): 21.2 (11–40). A tumor size ≥2 cm was found in 252 (50.7%). Most of them, 320 (64.4%), were in Stage I (AJCC 7th Edition). Following R35, 286 (57.5%) would have needed TT. Thus, they would have required a second surgery had they undergone TL. The indications for reintervention would have included lymph node involvement (35%), extrathyroidal extension (22.9%), aggressive subtype (8%), or vascular invasion (22.5%). No presurgical clinical data predict TT.

Conclusions

The appropriate management of low-risk PTC is unclear. Adherence to ATA R35 could lead to a huge increase in reinterventions when a TL is performed, though the need for them would be questionable. In our sample, more than half of patients (57.5%) who may undergo a TL for a seemingly low-risk PTC would have required a second operation to satisfy international guidelines, until better preoperative diagnostic tools become available.
Literature
1.
go back to reference J. Rojo Álvaro, B. Bermejo Fraile, E. Menéndez Torre, E. Ardanaz, M. Guevara, E. Anda Apiñániz, Increased incidence of thyroid cancer in Navarra (Spain). Evolution and clinical characteristics, 1986–2010. Endocrinología Diabetes y Nutrición 64, 303–309 (2017)CrossRef J. Rojo Álvaro, B. Bermejo Fraile, E. Menéndez Torre, E. Ardanaz, M. Guevara, E. Anda Apiñániz, Increased incidence of thyroid cancer in Navarra (Spain). Evolution and clinical characteristics, 1986–2010. Endocrinología Diabetes y Nutrición 64, 303–309 (2017)CrossRef
2.
go back to reference B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26, 1–133 (2016)CrossRef B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26, 1–133 (2016)CrossRef
3.
go back to reference F.A. Verburg, C. Aktolun, A. Chiti, S. Frangos, L. Giovanella, M. Hoffmann, I. Iakovou, J. Mihailovic, B.J. Krause, W. Langsteger et al. EANM and the EANM Thyroid Committee. Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging 43, 1001–1005 (2016)CrossRef F.A. Verburg, C. Aktolun, A. Chiti, S. Frangos, L. Giovanella, M. Hoffmann, I. Iakovou, J. Mihailovic, B.J. Krause, W. Langsteger et al. EANM and the EANM Thyroid Committee. Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging 43, 1001–1005 (2016)CrossRef
4.
go back to reference R. Udelsman, A.R. Shaha, Is total thyroidectomy the best possible surgical management for well-differentiated thyroid cancer? Lancet Oncology 6, 529–531 (2005)CrossRef R. Udelsman, A.R. Shaha, Is total thyroidectomy the best possible surgical management for well-differentiated thyroid cancer? Lancet Oncology 6, 529–531 (2005)CrossRef
5.
go back to reference C. Zafon, J.J. Díez, J.C. Galofré, D.S. Cooper, Nodular thyroid disease and thyroid cancer in the era of precision medicine. European Thyroid Journal 6, 65–74 (2017)CrossRef C. Zafon, J.J. Díez, J.C. Galofré, D.S. Cooper, Nodular thyroid disease and thyroid cancer in the era of precision medicine. European Thyroid Journal 6, 65–74 (2017)CrossRef
6.
go back to reference W.P. Kluijfhout, J.D. Pasternak, J. Lim, J.S. Kwon, M.R. Vriens, O.H. Clark, W.T. Shen, J.E. Gosnell, I. Suh, Q.Y. Duh, Frequency of high-risk characteristics requiring total thyroidectomy for 1–4 cm well-differentiated thyroid cancer. Thyroid 26, 820–824 (2016)CrossRef W.P. Kluijfhout, J.D. Pasternak, J. Lim, J.S. Kwon, M.R. Vriens, O.H. Clark, W.T. Shen, J.E. Gosnell, I. Suh, Q.Y. Duh, Frequency of high-risk characteristics requiring total thyroidectomy for 1–4 cm well-differentiated thyroid cancer. Thyroid 26, 820–824 (2016)CrossRef
7.
go back to reference P.W. Owens, T.P. McVeigh, E.J. Fahey, M. Bell, D.S. Quill, M.J. Kerin, A.J. Lowery, Differentiated thyroid cancer: how do current practice guidelines affect management? European Thyroid Journal 7, 319–326 (2018)CrossRef P.W. Owens, T.P. McVeigh, E.J. Fahey, M. Bell, D.S. Quill, M.J. Kerin, A.J. Lowery, Differentiated thyroid cancer: how do current practice guidelines affect management? European Thyroid Journal 7, 319–326 (2018)CrossRef
8.
go back to reference J.B. Choi, S.G. Lee, M.J. Kim, T.H. Kim, E.J. Ban, C.R. Lee, J. Lee, S.W. Kang, J.J. Jeong, K.H. Nam et al. Oncologic outcomes in patients with 1-cm to 4-cm differentiated thyroid carcinoma according to extent of thyroidectomy. Head and Neck 41, 56–63 (2019)PubMed J.B. Choi, S.G. Lee, M.J. Kim, T.H. Kim, E.J. Ban, C.R. Lee, J. Lee, S.W. Kang, J.J. Jeong, K.H. Nam et al. Oncologic outcomes in patients with 1-cm to 4-cm differentiated thyroid carcinoma according to extent of thyroidectomy. Head and Neck 41, 56–63 (2019)PubMed
9.
go back to reference B.H. Lang, T.W. Shek, K.Y. Wan, The significance of unrecognized histological high-risk features on response to therapy in papillary thyroid carcinoma measuring 1-4 cm: implications for completion thyroidectomy following lobectomy. Clinical Endocrinology 86, 236–242 (2017)CrossRef B.H. Lang, T.W. Shek, K.Y. Wan, The significance of unrecognized histological high-risk features on response to therapy in papillary thyroid carcinoma measuring 1-4 cm: implications for completion thyroidectomy following lobectomy. Clinical Endocrinology 86, 236–242 (2017)CrossRef
10.
go back to reference J.H. Park, J.H. Yoon, Lobectomy in patients with differentiated thyroid cancer: indications and follow-up. Endocrine Related Cancer 26, R381–R393 (2019)CrossRef J.H. Park, J.H. Yoon, Lobectomy in patients with differentiated thyroid cancer: indications and follow-up. Endocrine Related Cancer 26, R381–R393 (2019)CrossRef
11.
go back to reference D.S.A. McLeod, L. Zhang, C. Durante, D.S. Cooper, Contemporary debates in adult papillary thyroid cancer management. Endocrine Reviews 40, 1481–1499 (2019)CrossRef D.S.A. McLeod, L. Zhang, C. Durante, D.S. Cooper, Contemporary debates in adult papillary thyroid cancer management. Endocrine Reviews 40, 1481–1499 (2019)CrossRef
12.
go back to reference R.M. Gartland, C.C. Lubitz, Impact of extent of surgery on tumor recurrence and survival for papillary thyroid cancer patients. Annals of Surgical Oncology 25, 2520–2525 (2018)CrossRef R.M. Gartland, C.C. Lubitz, Impact of extent of surgery on tumor recurrence and survival for papillary thyroid cancer patients. Annals of Surgical Oncology 25, 2520–2525 (2018)CrossRef
13.
go back to reference S. Vargas-Pinto, M.A. Romero Arenas, Lobectomy compared to total thyroidectomy for low-risk papillary thyroid cancer: a systematic review. Journal of Surgery Research 242, 244–251 (2019)CrossRef S. Vargas-Pinto, M.A. Romero Arenas, Lobectomy compared to total thyroidectomy for low-risk papillary thyroid cancer: a systematic review. Journal of Surgery Research 242, 244–251 (2019)CrossRef
14.
go back to reference A.R. Shaha, Lobectomy vs total thyroidectomy - have we resolved the debate? International Journal of Surgery 38, 141–142 (2017)CrossRef A.R. Shaha, Lobectomy vs total thyroidectomy - have we resolved the debate? International Journal of Surgery 38, 141–142 (2017)CrossRef
15.
go back to reference K.Y. Bilimoria, D.J. Bentrem, C.Y. Ko, A.K. Stewart, D.P. Winchester, M.S. Talamonti, C. Sturgeon, Extent of surgery affects survival for papillary thyroid cancer. Annals of Surgery 246, 375–381 (2007)CrossRef K.Y. Bilimoria, D.J. Bentrem, C.Y. Ko, A.K. Stewart, D.P. Winchester, M.S. Talamonti, C. Sturgeon, Extent of surgery affects survival for papillary thyroid cancer. Annals of Surgery 246, 375–381 (2007)CrossRef
16.
go back to reference B.M. Barney, Y.J. Hitchcock, P. Sharma, D.C. Shrieve, J.D. Tward, Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head and Neck 33, 645–649 (2011)CrossRef B.M. Barney, Y.J. Hitchcock, P. Sharma, D.C. Shrieve, J.D. Tward, Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head and Neck 33, 645–649 (2011)CrossRef
17.
go back to reference S.R. Rajjoub, H. Yan, N.A. Calcatera, K. Kuchta, C.E. Wang, W. Lutfi, T.A. Moo-Young, D.J. Winchester, R.A. Prinz, Thyroid lobectomy is not sufficient for T2 papillary thyroid cancers. Surgery 163, 1134–1143 (2018)CrossRef S.R. Rajjoub, H. Yan, N.A. Calcatera, K. Kuchta, C.E. Wang, W. Lutfi, T.A. Moo-Young, D.J. Winchester, R.A. Prinz, Thyroid lobectomy is not sufficient for T2 papillary thyroid cancers. Surgery 163, 1134–1143 (2018)CrossRef
18.
go back to reference P.I. Haigh, D.R. Urbach, L.E. Rotstein, Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Annals of Surgical Oncology 12, 81–89 (2005)CrossRef P.I. Haigh, D.R. Urbach, L.E. Rotstein, Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Annals of Surgical Oncology 12, 81–89 (2005)CrossRef
19.
go back to reference A.H. Mendelsohn, D.A. Elashoff, E. Abemayor, M.A. St John, Surgery for papillary thyroid carcinoma: is lobectomy enough? Archives of Otorhinolaryngology-head & Neck. Archives of Otorhinolaryngology Head and Neck Surgery 136, 1055–1061 (2010)CrossRef A.H. Mendelsohn, D.A. Elashoff, E. Abemayor, M.A. St John, Surgery for papillary thyroid carcinoma: is lobectomy enough? Archives of Otorhinolaryngology-head & Neck. Archives of Otorhinolaryngology Head and Neck Surgery 136, 1055–1061 (2010)CrossRef
20.
go back to reference I.J. Nixon, I. Ganly, S.G. Patel, F.L. Palmer, M.M. Whitcher, R.M. Tuttle, A. Shaha, J.P. Shah, Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery 15, 571–579 (2012)CrossRef I.J. Nixon, I. Ganly, S.G. Patel, F.L. Palmer, M.M. Whitcher, R.M. Tuttle, A. Shaha, J.P. Shah, Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery 15, 571–579 (2012)CrossRef
21.
go back to reference K. Matsuzu, K. Sugino, K. Masudo, M. Nagahama, W. Kitagawa, H. Shibuya, K. Ohkuwa, T. Uruno, A. Suzuki, S. Magoshi et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World Journal of Surgery 38, 68–79 (2014)CrossRef K. Matsuzu, K. Sugino, K. Masudo, M. Nagahama, W. Kitagawa, H. Shibuya, K. Ohkuwa, T. Uruno, A. Suzuki, S. Magoshi et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World Journal of Surgery 38, 68–79 (2014)CrossRef
22.
go back to reference M.A. Adam, J. Pura, L. Gu, M.A. Dinan, D.S. Tyler, S.D. Reed, R. Scheri, S.A. Roman, J.A. Sosa, Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Annals of Surgery 260, 601–605 (2014)CrossRef M.A. Adam, J. Pura, L. Gu, M.A. Dinan, D.S. Tyler, S.D. Reed, R. Scheri, S.A. Roman, J.A. Sosa, Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Annals of Surgery 260, 601–605 (2014)CrossRef
23.
go back to reference M.J. Kim, M.C. Lee, G.H. Lee, H.S. Choi, S.W. Cho, S.J. Kim, K.E. Lee, Y.J. Park, D.J. Park, Extent of surgery did not affect recurrence during 7-years follow-up in papillary thyroid cancer sized 1-4 cm: preliminary results. Clinical Endocrinology 87, 80–86 (2017)CrossRef M.J. Kim, M.C. Lee, G.H. Lee, H.S. Choi, S.W. Cho, S.J. Kim, K.E. Lee, Y.J. Park, D.J. Park, Extent of surgery did not affect recurrence during 7-years follow-up in papillary thyroid cancer sized 1-4 cm: preliminary results. Clinical Endocrinology 87, 80–86 (2017)CrossRef
24.
go back to reference G. Li, R. Li, L. Song, W. Chen, K. Jiang, H. Tang, T. Wei, Z. Li, R. Gong, J. Lei et al. Implications of extrathyroidal extension invading only the strap muscles in papillary thyroid carcinomas. Thyroid 30, 57–64 (2020)CrossRef G. Li, R. Li, L. Song, W. Chen, K. Jiang, H. Tang, T. Wei, Z. Li, R. Gong, J. Lei et al. Implications of extrathyroidal extension invading only the strap muscles in papillary thyroid carcinomas. Thyroid 30, 57–64 (2020)CrossRef
25.
go back to reference J.S. Radowsky, R.S. Howard, H.B. Burch, A. Stojadinovic, Impact of degree of extrathyroidal extension of disease on papillary thyroid cancer outcome. Thyroid 24, 241–244 (2014)CrossRef J.S. Radowsky, R.S. Howard, H.B. Burch, A. Stojadinovic, Impact of degree of extrathyroidal extension of disease on papillary thyroid cancer outcome. Thyroid 24, 241–244 (2014)CrossRef
26.
go back to reference S.E. Moore, K. Kasaian, S. Jones, A. Melck, S.M. Wiseman, Clinical importance of bilateral disease in patients with papillary thyroid cancer. Canadian Journal of Surgery 59, 213–215 (2016)CrossRef S.E. Moore, K. Kasaian, S. Jones, A. Melck, S.M. Wiseman, Clinical importance of bilateral disease in patients with papillary thyroid cancer. Canadian Journal of Surgery 59, 213–215 (2016)CrossRef
27.
go back to reference B.S. Koo, H.S. Lim, Y.C. Lim, Y.H. Yoon, Y.M. Kim, Y.H. Park, K.S. Rha, Occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma. Annals of Surgical Oncology 17, 1101–1105 (2010)CrossRef B.S. Koo, H.S. Lim, Y.C. Lim, Y.H. Yoon, Y.M. Kim, Y.H. Park, K.S. Rha, Occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma. Annals of Surgical Oncology 17, 1101–1105 (2010)CrossRef
28.
go back to reference H. Mazeh, Y. Samet, D. Hochstein, I. Mizrahi, I. Ariel, A. Eid, H.R. Freund, Multifocality in well-differentiated thyroid carcinomas calls for total thyroidectomy. American Journal of Surgery 201, 770–775 (2011)CrossRef H. Mazeh, Y. Samet, D. Hochstein, I. Mizrahi, I. Ariel, A. Eid, H.R. Freund, Multifocality in well-differentiated thyroid carcinomas calls for total thyroidectomy. American Journal of Surgery 201, 770–775 (2011)CrossRef
29.
go back to reference Y. Ito, H. Masuoka, M. Fukushima, H. Inoue, M. Kihara, C. Tomoda, T. Higashiyama, Y. Takamura, K. Kobayashi, A. Miya et al. Excellent prognosis of patients with solitary T1N0M0 papillary thyroid carcinoma who underwent thyroidectomy and elective lymph node dissection without radioiodine therapy. World Journal of Surgery 34, 1285–1290 (2010)CrossRef Y. Ito, H. Masuoka, M. Fukushima, H. Inoue, M. Kihara, C. Tomoda, T. Higashiyama, Y. Takamura, K. Kobayashi, A. Miya et al. Excellent prognosis of patients with solitary T1N0M0 papillary thyroid carcinoma who underwent thyroidectomy and elective lymph node dissection without radioiodine therapy. World Journal of Surgery 34, 1285–1290 (2010)CrossRef
30.
go back to reference J.C. Galofré, The dilemma of papillary thyroid microcarcinoma management. To operate or not to operate, that is the question. Endocrinología, Diabetes y Nutrición 66, 469–471 (2019)CrossRef J.C. Galofré, The dilemma of papillary thyroid microcarcinoma management. To operate or not to operate, that is the question. Endocrinología, Diabetes y Nutrición 66, 469–471 (2019)CrossRef
31.
go back to reference J.J. Díez, J.C. Galofré, A. Oleaga, E. Grande, M. Mitjavila, P. Moreno, Grupo de Trabajo de Cáncer de Tiroides de la Sociedad Española de Endocrinología y Nutrición. Consensus statement for accreditation of multidisciplinary thyroid cancer units. Endocrinología y Nutrición 63, e1–e15 (2016)CrossRef J.J. Díez, J.C. Galofré, A. Oleaga, E. Grande, M. Mitjavila, P. Moreno, Grupo de Trabajo de Cáncer de Tiroides de la Sociedad Española de Endocrinología y Nutrición. Consensus statement for accreditation of multidisciplinary thyroid cancer units. Endocrinología y Nutrición 63, e1–e15 (2016)CrossRef
32.
go back to reference P. Perros, K. Boelaert, S. Colley, C. Evans, R.M. Evans, G. Gerrard Ba, J. Gilbert, B. Harrison, S.J. Johnson, T.E. Giles, L. Moss et al. British Thyroid Association. Guidelines for the management of thyroid cancer. Clinical Endocrinology 81(Suppl 1), 1–122 (2014)CrossRef P. Perros, K. Boelaert, S. Colley, C. Evans, R.M. Evans, G. Gerrard Ba, J. Gilbert, B. Harrison, S.J. Johnson, T.E. Giles, L. Moss et al. British Thyroid Association. Guidelines for the management of thyroid cancer. Clinical Endocrinology 81(Suppl 1), 1–122 (2014)CrossRef
Metadata
Title
The extent of surgery for low-risk 1–4 cm papillary thyroid carcinoma: a catch-22 situation. A retrospective analysis of 497 patients based on the 2015 ATA Guidelines recommendation 35
Authors
Emma Anda Apiñániz
Carles Zafon
Irati Ruiz Rey
Carolina Perdomo
Javier Pineda
Juan Alcalde
Marta García Goñi
Juan C. Galofré
Publication date
01-12-2020
Publisher
Springer US
Published in
Endocrine / Issue 3/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02371-9

Other articles of this Issue 3/2020

Endocrine 3/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine